Charles River initiated with an Outperform at RBC Capital

RBC Capital initiated coverage of Charles River (CRL) with an Outperform rating and $215 price target The firm likes the share setup, saying Charles River is well positioned for an inflection in preclinical research and development spend. The company’s 2026 operating margin estimates need to come, the analyst tells investors in a research note. RBC believes Charles River’s long-term targets for high-single-digit revenue growth will come back into focus in 2027, sooner than the Street expects.